Publications:128
Ernesto Guccione, PhD
About Me
During my PhD at the International Center for Genetic Engineering Biotechnology (ICGEB) I have studied the oncogenic functions of HPV E6/E7 viral proteins and the relevance of splicing in regulating E6 functions. My postdoctoral work at the European Institute of Oncology I studied the role of chromatin in defining c-MYC target site recognition. I have also identified PRMT6, a member of the Protein Arginine MethylTransferase (PRMT) family, as an important enzyme regulating transcriptional repression.
In 2008 I started my lab at A*STAR in Singapore where I was promoted to Research Director and Coordinated the program of Epigenetics and Diseases.
In 2019 I moved to the department of Oncological Sciences and Pharmacological Sciences at Icahn School of Medicine at Mount Sinai where I am currently an Associate Professor.
My lab has a long-standing interest in understanding basic mechanisms of transcriptional and post-transcriptional regulation in order to identify therapeutic opportunities in oncology.
Currently, we are interested in the function in development and disease of Protein MethylTrasnferases (PMTs) and in modulation of Alternative Splicing using Splice switching Antisense Oligonucleotide (AON)-based approaches.
Lab Website: Guccione Lab
Language
English
Position
PROFESSOR | Oncological Sciences, PROFESSOR | Pharmacological Sciences, PROFESSOR | Immunology & Immunotherapy
Research Topics
Cancer, Developmental Biology, Epigenetics, Post-Transcriptional Processing
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Development Regeneration and Stem Cells [DRS]
Education
MS, University of Bologna
PhD, International School for Advanced Studies (SISSA)/International Center for Genetic Engineering Biotechnology (ICGEB)
Post Doc, European Institute of Oncology
Research
The Guccione lab has a long-standing interest in understanding basic mechanisms of transcriptional and post-transcriptional regulation in order to identify therapeutic opportunities in oncology. Currently, we are interested in the function in development and disease of Protein MethylTrasnferases (PMTs) and in modulation of Alternative Splicing using Antisense Oligonucleotide (AON)-based approaches. We use biochemistry, mouse models and next generation sequencing techniques to understand the molecular mechanisms of action of candidate PMTs or specific isoforms. The range of techniques and approaches used in the lab has allowed us to characterize the mechanism of action of specific PMTs (e.g. PRMT5 and PRMT6) or oncogenic isoforms (e.g. MDM4l/s), which are now of great interest for their clinical applications.
Publications
Selected Publications
- Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinib. Ugne Balaseviciute, Júlia Huguet-Pradell, Jordi Abril-Fornaguera, Albert Gris-Oliver, Alex Rialdi, Elisa Fernández-Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho-Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet. Molecular Oncology
- A synergistic interaction between PRMT5 and LSD1 inhibitors in AML. Nesteene Joy Param, Elisa Arceci, Francesco Fiorentino, Luca Pignata, Denis Torre, Nayeli Gutiérrez-Trejo, Jia Yi Fong, Pierre Alexis Goy, Brenda Y. Han, Chiara Lambona, Elisabetta Di Bello, Carola Castiello, Marco Barone, Megan Schwarz, Cheryl Arrowsmith, Koichi Ito, Peggy Scherle, Dave Keng Boon Wee, Steven Ndoye, Tommaso Tabaglio, Anand D. Jeyasekharan, Manikandan Lakshmanan, Roberto Cirilli, Hansjörg Habisch, Tobias Madl, Andrea Mattevi, Sergio Valente, Antonello Mai, Ernesto Guccione. Science advances
- Transposable element–gene chimera cartography, origination and role in enhancing transcriptome plasticity. Youngseo Cheon, Erik Glen Alvstad, Denis Torre, Daniel Tu Quach, Jennifer Nguyen, Kwangbeom Hyun, Mingqi Zhou, Tianxiong Yu, Liang Liu, Yoseop Yoon, Fairlie Reese, Lauren Faraone, Yingcong Li, Frederick J. Arnold, Yesai S. Fstkchyan, Uttiya Basu, Evgeny Kvon, Enza Maria Valente, Jessica Sook Yuin Ho, Minji Byun, Ernesto Guccione, Yongsheng Shi, Zhiping Weng, Marcus Seldin, Ivan Marazzi. Nature Structural and Molecular Biology
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Guccione during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Board Service
- Prometeo Therapeutics
Consulting or Other Professional Services
Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership- Hyris
- IFOM
- Prometeo Therapeutics
Editorial Services
- Epigenomes
Equity
(Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)- Prometeo Therapeutics
Founder/Co-Founder/Partner
- Prometeo Therapeutics
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.